Novozymes confirms 2026 organic sales growth outlook of 7-8%

PUBT · 1d ago
Novozymes confirms 2026 organic sales growth outlook of 7-8%
  • Novozymes confirmed its 2026 organic sales growth outlook of 7-8%.
  • Adjusted EBITDA margin is expected at the higher end of the 37-38% range.
  • Fourth-quarter organic sales growth is projected in the high single digits.
  • Full-year growth excludes an expected drag of close to 1 percentage point from exiting certain countries.
  • Nine-month organic sales growth reached 7%, with an adjusted EBITDA margin of 37.9%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.